Prevalence of Suicidal Risk in Psychiatric Settings
RSCP
1 other identifier
observational
262
1 country
1
Brief Summary
France is among the countries with one of the highest suicide rates in the world, far ahead of its neighboring nations \[Wasserman et al., 2012\]. Suicide represents the second leading cause of death among 15-24-year-olds, just after road accidents, and the leading cause of death among 25-34-year-olds. In this context, a better utilization of all components of the healthcare system seems highly desirable, particularly through greater involvement of community psychiatrists in suicide prevention strategies. Approximately 25% of individuals who die by suicide have consulted a psychiatrist in the month preceding their death \[Luoma et al., 2002\], yet few data are available on this topic, especially regarding consultations with community psychiatrists outside of hospital settings. Study objectives Main objective To assess the prevalence of suicidal risk during the 15 days preceding an outpatient psychiatric consultation in the Clermont-Ferrand area. Main secondary objectives
- To describe the recruited population and potentially associated factors (age, sex, etc.).
- To assess the psychological pain of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst.
- To assess the self-esteem of these individuals over the same period when suicidal thoughts are strongest, or, if absent, when they feel at their worst.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2025
CompletedFirst Submitted
Initial submission to the registry
July 27, 2026
CompletedFirst Posted
Study publicly available on registry
August 4, 2026
CompletedAugust 4, 2026
November 1, 2025
Same day
July 27, 2026
July 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
score at scale a risk suicidal of Ducher (aRSD)
aRSD scale score from 0 to 10 (worse is 10)
Day 1
Secondary Outcomes (2)
SEST
Day 1
VAST
Day 1
Eligibility Criteria
patient consulting at the psychiatrist's office
You may qualify if:
- Any adult patient consulting at the psychiatrist's office during the recruitment period (regardless of the reason for consultation) and who has provided consent to participate in this study.
You may not qualify if:
- Minor patient or refusal to participate in the study.
- Patient who has already completed the self-questionnaires previously (e.g., second consultation within the same week).
- Patient unable to understand or complete the self-questionnaires (due to cognitive impairment or insufficient understanding of the French language).
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
CHU
Clermont-Ferrand, 63000, France
MeSH Terms
Conditions
Study Officials
- STUDY CHAIR
Pierre-Michel Llorca
CHU de Clermont-Fd
Study Design
- Study Type
- observational
- Observational Model
- ECOLOGIC OR COMMUNITY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 27, 2026
First Posted
August 4, 2026
Study Start
May 1, 2025
Primary Completion
May 1, 2025
Study Completion
June 30, 2025
Last Updated
August 4, 2026
Record last verified: 2025-11